Netscientific expects shareholders to reject plan to delist from AIM and become private company
NetScientific has decided to postpone its general meeting.
Company
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
424 stories · page 10 of 22
NetScientific has decided to postpone its general meeting.
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio compani
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun
The transatlantic healthcare IP commercialisation group announced on 26 November 2018 that it had decided to conduct a review of the various strategic options open to it, one of which was a sale
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's maor movers, including Carnival, EKF, Chamberlin, Panthera, NetScientific and Yu Group
The board believes that the market is undervaluing NetScientific's portfolio
"Investors aren’t willing to forgive Fed Chair Jeremy Powell yet; a soft open on Wall Street threatens to drag the FTSE lower into the close," said Fiona Cincotta at City Index
Bosses believe the market is undervaluing the strength of NetScientific’s portfolio, and as such, thinks the best way to maximise shareholder value is to sell off all or parts of the business
The company said the all-share merger was expected to create a publicly traded biotech company specialising in immune-oncology and treatments for early and late-stage cancer
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's poppers and droppers, including JD Wetherspoon, Gattaca, Renewi, AdEPT, The Works, Coca-Cola HBC and Micro Focus
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells
Investments and investor services
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some big winners and losers in the UK equity market during Thursday's trading session